Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

Submission to be reviewed under FDA real-time oncology review and Project Orbis

100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh

Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40